Stem and progenitor cell alterations in myelodysplastic syndromes

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Recent studies have demonstrated that myelodysplastic syndromes (MDSs) arise from a small population of diseaseinitiating hematopoietic stem cells (HSCs) that persist and expand through conventional therapies and are major contributors to disease progression and relapse. MDS stem and progenitor cells are characterized by key founder and driver mutations and are enriched for cytogenetic alterations. Quantitative alterations in hematopoietic stem and progenitor cell (HSPC) numbers are also seen in a stagespecific manner in human MDS samples as well as in murine models of the disease. Overexpression of several markers such as interleukin-1 (IL-1) receptor accessory protein (IL1RAP), CD99, T-cell immunoglobulin mucin-3, and CD123 have begun to differentiate MDS HSPCs from healthy counterparts. Overactivation of innate immune components such as Toll-like receptors, IL-1 receptor-associated kinase/ tumor necrosis factor receptor-associated factor-6, IL8/CXCR2, and IL1RAP signaling pathways has been demonstrated in MDS HSPCsandisbeing targeted therapeutically in preclinical and early clinical studies. Other dysregulated pathways such as signal transducer and activator of transcription 3, tyrosine kinase with immunoglobulinlike and EGF-like domains 1/angiopoietin-1, p21-activated kinase, microRNA 21, and transforming growth factor b are also being explored as therapeutic targets against MDS HSPCs. Taken together, these studies have demonstrated that MDS stem cells are functionally critical for the initiation, transformation, and relapse of disease and need to be targeted therapeutically for future curative strategies in MDSs.

Original languageEnglish (US)
Pages (from-to)1586-1594
Number of pages9
JournalBlood
Volume129
Issue number12
DOIs
StatePublished - Mar 23 2017

Fingerprint

Myelodysplastic Syndromes
Stem Cells
Stem cells
Interleukin-1 Receptor Accessory Protein
Mucin-3
Interleukin-1 Receptor-Associated Kinases
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins
p21-Activated Kinases
Angiopoietin-1
STAT3 Transcription Factor
Interleukin-1 Receptors
T-cells
Hematopoietic Stem Cells
Toll-Like Receptors
Accessories
Transforming Growth Factors
MicroRNAs
Interleukin-8
Epidermal Growth Factor
Protein-Tyrosine Kinases

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Stem and progenitor cell alterations in myelodysplastic syndromes. / Shastri, Aditi; Will, Britta; Steidl, Ulrich G.; Verma, Amit K.

In: Blood, Vol. 129, No. 12, 23.03.2017, p. 1586-1594.

Research output: Contribution to journalReview article

@article{dbf034c8af5b43b4b4610a37410b7c90,
title = "Stem and progenitor cell alterations in myelodysplastic syndromes",
abstract = "Recent studies have demonstrated that myelodysplastic syndromes (MDSs) arise from a small population of diseaseinitiating hematopoietic stem cells (HSCs) that persist and expand through conventional therapies and are major contributors to disease progression and relapse. MDS stem and progenitor cells are characterized by key founder and driver mutations and are enriched for cytogenetic alterations. Quantitative alterations in hematopoietic stem and progenitor cell (HSPC) numbers are also seen in a stagespecific manner in human MDS samples as well as in murine models of the disease. Overexpression of several markers such as interleukin-1 (IL-1) receptor accessory protein (IL1RAP), CD99, T-cell immunoglobulin mucin-3, and CD123 have begun to differentiate MDS HSPCs from healthy counterparts. Overactivation of innate immune components such as Toll-like receptors, IL-1 receptor-associated kinase/ tumor necrosis factor receptor-associated factor-6, IL8/CXCR2, and IL1RAP signaling pathways has been demonstrated in MDS HSPCsandisbeing targeted therapeutically in preclinical and early clinical studies. Other dysregulated pathways such as signal transducer and activator of transcription 3, tyrosine kinase with immunoglobulinlike and EGF-like domains 1/angiopoietin-1, p21-activated kinase, microRNA 21, and transforming growth factor b are also being explored as therapeutic targets against MDS HSPCs. Taken together, these studies have demonstrated that MDS stem cells are functionally critical for the initiation, transformation, and relapse of disease and need to be targeted therapeutically for future curative strategies in MDSs.",
author = "Aditi Shastri and Britta Will and Steidl, {Ulrich G.} and Verma, {Amit K.}",
year = "2017",
month = "3",
day = "23",
doi = "10.1182/blood-2016-10-696062",
language = "English (US)",
volume = "129",
pages = "1586--1594",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Stem and progenitor cell alterations in myelodysplastic syndromes

AU - Shastri, Aditi

AU - Will, Britta

AU - Steidl, Ulrich G.

AU - Verma, Amit K.

PY - 2017/3/23

Y1 - 2017/3/23

N2 - Recent studies have demonstrated that myelodysplastic syndromes (MDSs) arise from a small population of diseaseinitiating hematopoietic stem cells (HSCs) that persist and expand through conventional therapies and are major contributors to disease progression and relapse. MDS stem and progenitor cells are characterized by key founder and driver mutations and are enriched for cytogenetic alterations. Quantitative alterations in hematopoietic stem and progenitor cell (HSPC) numbers are also seen in a stagespecific manner in human MDS samples as well as in murine models of the disease. Overexpression of several markers such as interleukin-1 (IL-1) receptor accessory protein (IL1RAP), CD99, T-cell immunoglobulin mucin-3, and CD123 have begun to differentiate MDS HSPCs from healthy counterparts. Overactivation of innate immune components such as Toll-like receptors, IL-1 receptor-associated kinase/ tumor necrosis factor receptor-associated factor-6, IL8/CXCR2, and IL1RAP signaling pathways has been demonstrated in MDS HSPCsandisbeing targeted therapeutically in preclinical and early clinical studies. Other dysregulated pathways such as signal transducer and activator of transcription 3, tyrosine kinase with immunoglobulinlike and EGF-like domains 1/angiopoietin-1, p21-activated kinase, microRNA 21, and transforming growth factor b are also being explored as therapeutic targets against MDS HSPCs. Taken together, these studies have demonstrated that MDS stem cells are functionally critical for the initiation, transformation, and relapse of disease and need to be targeted therapeutically for future curative strategies in MDSs.

AB - Recent studies have demonstrated that myelodysplastic syndromes (MDSs) arise from a small population of diseaseinitiating hematopoietic stem cells (HSCs) that persist and expand through conventional therapies and are major contributors to disease progression and relapse. MDS stem and progenitor cells are characterized by key founder and driver mutations and are enriched for cytogenetic alterations. Quantitative alterations in hematopoietic stem and progenitor cell (HSPC) numbers are also seen in a stagespecific manner in human MDS samples as well as in murine models of the disease. Overexpression of several markers such as interleukin-1 (IL-1) receptor accessory protein (IL1RAP), CD99, T-cell immunoglobulin mucin-3, and CD123 have begun to differentiate MDS HSPCs from healthy counterparts. Overactivation of innate immune components such as Toll-like receptors, IL-1 receptor-associated kinase/ tumor necrosis factor receptor-associated factor-6, IL8/CXCR2, and IL1RAP signaling pathways has been demonstrated in MDS HSPCsandisbeing targeted therapeutically in preclinical and early clinical studies. Other dysregulated pathways such as signal transducer and activator of transcription 3, tyrosine kinase with immunoglobulinlike and EGF-like domains 1/angiopoietin-1, p21-activated kinase, microRNA 21, and transforming growth factor b are also being explored as therapeutic targets against MDS HSPCs. Taken together, these studies have demonstrated that MDS stem cells are functionally critical for the initiation, transformation, and relapse of disease and need to be targeted therapeutically for future curative strategies in MDSs.

UR - http://www.scopus.com/inward/record.url?scp=85016256866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016256866&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-10-696062

DO - 10.1182/blood-2016-10-696062

M3 - Review article

C2 - 28159737

AN - SCOPUS:85016256866

VL - 129

SP - 1586

EP - 1594

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -